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Sensitivity of Colorectal Cancer to 
Arginine Deprivation Therapy is 
Shaped by Differential Expression 
of Urea Cycle Enzymes
Constantinos Alexandrou1, Saif Sattar Al-Aqbi1,2, Jennifer A. Higgins1, William Boyle3, 
Ankur Karmokar1, Catherine Andreadi1, Jin-Li Luo1, David A. Moore4, Maria Viskaduraki5, 
Matthew Blades5, Graeme I. Murray6, Lynne M. Howells1, Anne Thomas1, Karen Brown1, 
Paul N. Cheng7 & Alessandro Rufini1
Tumors deficient in the urea cycle enzymes argininosuccinate synthase-1 (ASS1) and ornithine 
transcarbamylase (OTC) are unable to synthesize arginine and can be targeted using arginine-
deprivation therapy. Here, we show that colorectal cancers (CRCs) display negligible expression of 
OTC and, in subset of cases, ASS1 proteins. CRC cells fail to grow in arginine-free medium and dietary 
arginine deprivation slows growth of cancer cells implanted into immunocompromised mice. Moreover, 
we report that clinically-formulated arginine-degrading enzymes are effective anticancer drugs in 
CRC. Pegylated arginine deiminase (ADI-PEG20), which degrades arginine to citrulline and ammonia, 
affects growth of ASS1-negative cells, whereas recombinant human arginase-1 (rhArg1peg5000), which 
degrades arginine into urea and ornithine, is effective against a broad spectrum of OTC-negative CRC 
cell lines. This reflects the inability of CRC cells to recycle citrulline and ornithine into the urea cycle. 
Finally, we show that arginase antagonizes chemotherapeutic drugs oxaliplatin and 5-fluorouracil (5-
FU), whereas ADI-PEG20 synergizes with oxaliplatin in ASS1-negative cell lines and appears to 
interact with 5-fluorouracil independently of ASS1 status. Overall, we conclude that CRC is amenable 
to arginine-deprivation therapy, but we warrant caution when combining arginine deprivation with 
standard chemotherapy.
Arginine is a semi-essential amino acid in adult mammals that is required for protein synthesis, and is the main 
substrate for the biosynthesis of nitric oxide, polyamines, proline, creatine, and agmantine1. Moreover, arginine, 
together with leucine, is chiefly responsible for the activation of the mTOR pathway, which in turn stimulates 
protein translation and other metabolic pathways, such as lipid metabolism and nucleotide biosynthesis2. Under 
physiological conditions, cells satisfy their arginine requirements through direct uptake from the bloodstream 
and/or through biosynthesis mediated by urea cycle enzymes. Two main enzymes are necessary to produce argi-
nine; ASS1 condensates citrulline and aspartate to form argininosuccinate, which is then converted to arginine 
and fumarate by argininosuccinate lyase (ASL) (Supplementary Fig. S1)1.
A variety of cancers display reduced expression of ASS1 and, to a lesser extent, ASL3,4. These tumors are una-
ble to synthesize arginine and are therefore auxotrophic, i.e. depending on external supplementation of arginine 
for their growth and survival. Resolute efforts to harness this metabolic vulnerability have led to the develop-
ment of arginine deprivation therapies enabled by the availability of arginine degrading enzymes5. Two com-
pounds are currently under clinical evaluation in several malignancies: mycoplasma-derived arginine deiminase 
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(ADI-PEG20) and human arginase-1 (rhArg1peg5000, BCT-100)6,7. ADI-PEG20 degrades arginine into citrul-
line and ammonia, whereas arginase hydrolyses arginine into urea and ornithine. Cells lacking ASS1 or ASL are 
incapable of recycling citrulline and ornithine and are therefore susceptible to arginine deprivation.
ASS1 expression is transcriptionally regulated. In some tumors, such as glioblastoma, bladder cancer and 
hepatocellular carcinoma, methylation of the promoter region of the ASS1 gene mediates its silencing; alterna-
tively, hypoxia-inducible factor 1α (HIF1α)-mediated repression of the ASS1 promoter has also been reported in 
cancers such as melanoma4,8–15. Traditionally, ASS1 has been adopted as the predictive biomarker for sensitivity to 
arginine deprivation therapy5. Hence, tumors with low expression of ASS1 have been extensively tested for their 
response to arginine degrading enzymes, whereas tumors with higher expression of ASS1, including CRC16, have 
been deemed ineligible to arginine deprivation therapy. Nonetheless, mounting evidence indicates that mod-
ulation of other urea cycle enzymes, such as OTC, can cause arginine auxotrophy and sensitivity to arginine 
deprivation therapies4,17–19.
Here, we unmask a striking arginine auxotrophy in CRC. We show that CRC cell lines are unable to prolif-
erate in arginine-free media and their growth in vivo is diminished by administration of an arginine-free diet. 
Mechanistically, we identify a methylation-independent downregulation of the OTC enzyme in CRC. Reduced 
OTC expression correlates with sensitivity of CRC cell lines to rhArg1peg5000 treatment in vitro and in vivo, 
independently of ASS1 expression. Indeed, resistance to arginase treatment necessitates recycling of ornithine 
into the urea cycle. This event is mediated by the mitochondrial enzyme OTC, which conjugates ornithine and 
carmaboylphosphate, a compound synthesized by mitochondrial carmaboylphosphate synthase 1 (CPS1), to 
form citrulline (Supplementary Fig. S1A). Intriguingly, we also describe a subset of CRC specimens and cell lines 
expressing low levels of ASS1 and responsive to ADI-PEG20 treatment. Finally, using the Chou-Talalay method 
for drug combination, we report the feasibility of using arginine deprivation therapy in combination with cur-
rent chemotherapeutic regimens for CRC. Overall, our results reveal that CRC is amenable to treatment with 
arginine-deprivation therapy.
Results
CRC cell lines display arginine auxotrophy. To assess whether external arginine supplementation is nec-
essary to sustain CRC growth, we cultured CRC cell lines in arginine-free medium or in a control medium con-
taining all amino acids. Notably, all cell lines tested failed to grow in the absence of arginine (Fig. 1A), indicating 
auxotrophy. The halted growth was accompanied by an arrest of DNA replication (Fig. 1B and C) and decreased 
expression of the cell cycle marker Cyclin D1 (Fig. 1D), and was reverted upon arginine repletion (Supplementary 
Fig. S1B). Consistent with the role of arginine in regulating mTOR signaling, we observed decreased mTOR 
activity, as indicated by the loss of the higher molecular weights rapamycin-sensitive phosphosites of the 4E-BP1 
protein20 (Supplementary Fig. S2).
To investigate whether the identified arginine addiction prevails in vivo, HCT116 cells where subcutaneously 
injected in immunocompromised athymic nude mice. After injection, mice were randomized to an arginine-free 
diet or a control diet (0.83% arginine) and tumor growth measured by calipers. Nutritional deprivation of argi-
nine was effective in slowing tumor growth, as demonstrated by diminished tumor volume and weight (Fig. 1E 
and F and Supplementary Fig. S3). Notably, dietary arginine deprivation did not affect animal body weight during 
the 35-day duration of the experiment (Fig. 1G). Overall, these findings identify arginine auxotrophy as a meta-
bolic vulnerability in CRC.
Downregulation of OTC and ASS1 expression in CRC. To investigate the mechanism responsible for 
the arginine dependence of CRC, we scored a TMA cohort, consisting of over 600 cases of CRC (Supplementary 
Table S1), for expression of OTC and ASS1 proteins. OTC expression was low or absent in virtually all cases. 
Interestingly, we also identified a subset of CRC patients (~18%) that expressed low or undetectable ASS1 levels 
(Fig. 2A and B, Supplementary Fig. S4).
Low expression of OTC and ASS1 was then confirmed by assessment of protein levels in a panel of CRC cells 
lines (Fig. 2C). No cell line showed evidence of OTC expression, which was promptly detected in control human 
liver. With regard to ASS1, its expression pattern in cell lines mirrored the heterogeneity observed in TMA; 
SW480 cells showed sustained expression of the enzyme, HCT116 cells expressed ASS1 moderately, whereas the 
expression of the enzyme was absent in HT29 and RKO cell lines. Finally, we analyzed gene expression datasets 
using the online platforms CancerMA and Oncomine21,22 and we confirmed downregulation of the OTC gene 
expression in colorectal tumors (Supplementary Fig. S5).
CpG island methylator phenotype (CIMP), which causes epigenetic gene silencing through methylation of 
cytosine residues at CpG-rich DNA sequences, contributes to the progression of CRC23. Both RKO and HT29 
cells are CIMP positive24. Hence, in the light of the reported role of promoter methylation in mediating silencing 
of the genes coding for the urea cycle enzymes, we investigated whether reversion of DNA methylation with the 
DNA methylase inhibitor 5-azacytidine (5-AZA) could rescue expression of ASS1 and OTC. Our results indicate 
that ASS1 suppression in RKO is indeed methylation-dependent, whereas CIMP is unlikely to mediate the loss 
of ASS1 in HT29. On the other hand, 5-AZA treatment did not rescue OTC expression in any of the cell line 
analyzed, suggesting that the regulation of OTC gene is not regulated through promoter methylation (Fig. 2C).
CRC cell lines are sensitive to arginine deprivation by rhArg1peg5000. Prompted by the marked 
arginine addiction of CRC cell lines and the impaired expression of urea cycle enzymes in cancer patients, we 
tested the feasibility of targeting CRC using pharmacological arginine deprivation. Because of the prevalent loss 
of OTC expression, we investigated whether depletion of arginine using rhArg1peg5000 could affect CRC cell 
growth. We found that all cell lines tested, independently of ASS1 expression, showed a robust, dose-dependent 
decrease in cell number upon rhArg1peg5000 treatment, with IC50 concentrations lower than 0.1 μg/ml (Fig. 3A). 
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Figure 1. Arginine auxotrophy in CRC. (A) Growth curves of the indicated cell lines with or without arginine 
supplementation. Data are presented as mean ± SEM of three independent experiments. (B) Representative 
flow cytometry scatterplots of EdU incorporation in HCT116, RKO, HT29 and SW480 CRC cell lines grown in 
control medium or arginine-free medium for 24 h. EdU was measured using the Click-iT® EdU Alexa Fluor® 
kit and total DNA stained using FxCycle™ Violet Stain. (C) Quantification of EdU incorporation from three 
independent experiments. Data are presented as mean ± SEM, two-tailed t-test. *P < 0.05, ***P < 0.001. (D) 
Western blot analysis of Cyclin D1 (CycD1) protein expression in HCT116, RKO and SW480 CRC cell lines 
following arginine deprivation for the indicated times. Actin was used as endogenous loading control. Original 
western blots are reported in Supplementary Fig. S15. (E) Graph showing the growth of xenografted HCT116 
cells in immunocompromised mice fed a control diet or an arginine-free diet. Data are plotted as mean ± SEM 
and were analyzed using mixed linear regression analysis (P = 0.03; P < 0.05 indicates a statistically significant 
difference in tumor growth rate between control and treated animals over time). (F) Weight of excised tumor 
measured at endpoint. Data are plotted as mean ± SEM. *P < 0.05, two-tailed t-test (n = 4 animal per group). 
(G) Animal body weights at endpoint plotted as mean ± SEM. No statistical differences were detected between 
the two diet groups, two-tailed t-test (n = 4 animals per group).
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To explore the mechanism responsible for the observed growth reduction, we measured cellular proliferation 
using the EdU incorporation assay and found that arginine depletion led to a sharp decrease in DNA synthesis 
(Fig. 3B and C), indicative of proliferative arrest. In agreement with this result, arginine-deprived cells displayed 
reduced expression of the cell cycle markers Cyclin D3 and Cyclin D1 (Fig. 3D and E). Notably, rhArg1peg5000 
treatment elicited expression of ASS1 in HCT116, RKO and HT29 (Supplementary Fig. S6). ASS1 expression also 
correlated with enhanced c-Myc expression in RKO and HT29 cells, in line with data showing c-Myc-mediated 
ASS1 re-expression in cells treated with arginine deprivation therapy25. Intriguingly, no compensatory expression 
of OTC was observed during the 72 h treatment (Supplementary Fig. S7).
Few floating cells were observed in the plates treated with rhArg1peg5000, possibly signifying a marginal 
induction of cell death. Indeed, the apoptotic marker cleaved-PARP was induced in arginine-deprived HCT116 
and RKO cells (Supplementary Fig. S8).
Next, we investigated whether rhArg1peg5000 treatment affects the mTOR pathway in a way similar to that 
observed in arginine-free medium. To this end, the phosphorylation status of two main mTOR downstream tar-
gets, the ribosomal S6 protein and 4E-BP1, was investigated by western blotting over a short (up to 8 h) and long 
(up to 72 h) time course. However, we did not observe durable and consistent changes in phosphorylation levels 
of mTOR targets (Supplementary Fig. S9).
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Figure 2. Reduced expression of OTC and ASS1 in CRC. (A) OTC and (B) ASS1 H-score were assessed on 
CRC TMA. Representative histo-spots are shown on the left. The bar graphs indicate H-score distribution 
according to Duke’s stage, whereas the distribution of protein expression within the whole TMA cohort is 
reported in the pie chart. *P < 0.05 (C) Western blot analysis of OTC and ASS1 after 72 h treatment with 5 µM 
5-Azacytidine (5-AZA). Human liver extract was used as positive control for urea cycle enzymes, actin was used 
as endogenous loading control. Original western blots are reported in Supplementary Fig. S15.
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Figure 3. CRC cells are sensitive to arginase treatment. (A) Dose-Response Non-Linear Regression Curves and 
IC50 values of the indicated CRC cell lines treated with the rhArg1peg5000. The percentage (%) of cell growth 
was calculated relative to the cell numbers in corresponding PBS-treated control samples, which was selected as 
100%. IC50 values were obtained from non-linear regression analysis of concentration of the drug vs response 
curves. The results were obtained from three independent experiments. Quadruplicate samples were assessed 
for cell growth after a 6-day period of treatment by cell counting for each individual experiment. The error 
bars represent ± SEM. (B) Representative flow cytometry scatterplots of EdU incorporation in HCT116, RKO, 
HT29 and SW480 CRC cell lines after 72 h treatment with rhArg1peg5000 (0.5 μg/mL) or PBS-vehicle control. 
EdU was measured using the Click-iT® EdU Alexa Fluor® kit and total DNA stained using FxCycle™ Violet 
Stain. (C) Quantification of EdU incorporation from three independent experiments. Data are presented as 
mean ± SEM. *P < 0.05, ****P < 0.0001, two-tailed t-test. (D) Western blot analysis of the cell cycle markers 
Cyclin D1 and D3 in cells treated for the indicated time with rhArg1peg5000 (0.5 μg/mL). Actin was used 
as endogenous loading control. (E) Quantification of Cyclin D1 and D3 protein expression from triplicate 
experiments. Original western blots are reported in Supplementary Fig. S15. Data are presented as mean ± SEM. 
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, two-way ANOVA.
www.nature.com/scientificreports/
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rhArg1peg5000 reduces tumor growth in vivo. To test whether arginine deprivation mediated by 
rhArg1peg5000 could impair tumor growth in vivo, we subcutaneously implanted ASS1-negative RKO cells 
and ASS1-positive SW480 cells into the hind flanks of immunocompromised athymic nude mice, which were 
then randomized to twice a week treatment schedule (0.5 mg of rhArg1peg5000 per animal) or vehicle con-
trol. Arginase administration significantly slowed tumor growth in animals into which either cell line had been 
implanted (Fig. 4A). Pegylated arginine was well tolerated and there was no difference in body weight recorded 
between control and treated animals (Supplementary Fig. S10).
Western blotting analysis with antibodies selective for the human protein confirmed robust expression of 
ASS1 in SW480-derived tumors, as well as ASS1 negativity in RKO xenograft samples (Fig. 4B). Notably, no 
expression of OTC was detected in tumor isolated from rhArg1peg5000 treated animals (Fig. 4B). These findings 
suggest that tumors did not acquire resistance against arginase through re-expression of urea cycle enzymes, at 
least in the time frame of these experiments.
Overall, these data indicate that CRC cells are sensitive to pharmacological depletion of arginine via 
pegylated-arginase in an ASS1-independent fashion.
CRC cell lines are sensitive to arginine deprivation by ADI-PEG20. As described above, RKO 
and HT29 cell lines do not express detectable ASS1 protein, and around 20% of CRC patients present with no 
or low expression of this biomarker (Fig. 2B and C). Hence, we investigate whether the mycoplasma-derived 
enzyme arginine deiminase could represent an alternative treatment opportunity for those patients. As expected, 
ASS1-positive SW480 cell lines were resistant to treatment with ADI-PEG20 in vitro, whereas ASS1-negative 
HT29 and RKO showed an exquisite sensitivity to ADI-PEG20-mediated arginine deprivation, with an iden-
tical IC50 of 0.034 μg/mL (Fig. 5A). In agreement with recently reported findings26,27, HCT116 growth was 
greatly reduced by ADI-PEG20, despite detectable levels of ASS1 (Fig. 5A). The reason for the HCT116 sensi-
tivity to ADI-PEG20 is unclear, as HCT116 cells also express ASL enzyme26. Others have attributed the effect 
of ADI-PEG20 treatment to downregulation of the mTOR pathway and induction of the unfolded protein 
Figure 4. Pharmacological depletion of arginine using rhArg1peg5000 reduces tumor growth in vivo. (A) 
Tumor growth in athymic nude mice subcutaneously injected with 106 RKO or SW480 CRC cells. Mice 
were randomized into Control (n = 8) and Treatment (n = 8) groups. Treated mice were administered 
intraperitoneally with 0.5 mg of rhArg1peg5000/animal twice a week, while control mice were injected with 
an equal volume of PBS. Data are plotted as mean ± SEM and were analyzed using mixed linear regression 
analysis (P = 0.012 for RKO and P = 0.03 for SW480, P < 0.05 indicates a statistically significant difference in 
tumor growth rate between control and treated animals over time). (B) Western blotting of lysates from tumor 
xenografts for assessment of urea cycle enzymes OTC and ASS1. Human liver lysate was used as a positive 
control and actin as endogenous loading control. Original western blots are reported in Supplementary Fig. S15.
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Figure 5. CRC cells are sensitive to arginine deiminase treatment. (A) Dose-Response Non-Linear Regression 
Curves and IC50 values of the indicated CRC cell lines treated with the ADI-PEG20. The percentage (%) of cell 
growth was calculated relative to the cell numbers in corresponding PBS-treated control samples, which was 
selected as 100%. IC50 values were obtained from non-linear regression analysis of concentration of the drug vs 
response curves. The results were obtained from three independent experiments. Quadruplicate samples were 
assessed for cell growth after a 6-day period of treatment by cell counting for each individual experiment. The 
error bars represent ±SEM. (B) Representative flow cytometry scatterplots of EdU incorporation in HCT116, 
RKO, HT29 and SW480 CRC cell lines after 72 h treatment with ADI-PEG20 (1 μg/mL) or PBS-vehicle control. 
EdU was measured using the using Click-iT® EdU Alexa Fluor® kit and total DNA stained using FxCycle™ 
Violet Stain. (C) Quantification of EdU incorporation from three independent experiments. Data are presented 
as mean ± SEM. *P < 0.05, ****P < 0.0001, two-tailed t-test. (D) Western blot analysis of the cell cycle markers 
Cyclin D1 and D3 and the urea cycle enzyme ASS1 in cells treated for the indicated time with ADI-PEG20 
(1 μg/mL). Actin was used as endogenous loading control. Original western blots are reported in Supplementary 
Fig. S15. (E) Quantification of Cyclin D1 and D3 protein expression from triplicate experiments. Data are 
presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, two-way ANOVA.
www.nature.com/scientificreports/
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response26, a possibility corroborated by the reduced phosphorylation of the mTOR targets 4E-BP1 and S6 after 
72 h of arginine deiminase treatment (Supplementary Fig. S11).
When proliferation was assessed after 72 h exposure to ADI-PEG20, we noticed a significant reduction of EdU 
incorporation only in ASS1-negative cells, but not in ASS1-positive SW480 and HCT116 (Fig. 5B and C). Further 
analysis indicated that, in all ADI-PEG20 sensitive cell lines, expression of the cell cycle markers Cyclin D1 and 
D3 was reduced 24 h to 48 h after drug treatment, but had returned to normal levels at the time point of the cell 
cycle analysis (72 h) (Fig. 5D and E). Similarly, the expression of ASS1 was boosted by ADI-PEG20 treatment 
(Fig. 5D). These findings could explain why DNA synthesis was still substantial at the 72 h time point of arginine 
deprivation, and they indicate the possibility of rapidly ensuing resistance.
ADI-PEG20 reduces tumor growth in vivo. To determine whether ADI-PEG20 could slow tumor growth 
in vivo, ASS1-negative RKO cells were subcutaneously implanted into nude mice, which were then randomly allo-
cated to either treatment (5IU of ADI-PEG20/animal/week) or vehicle control groups. ADI-PEG20 administra-
tion reduced tumor volume (Fig. 6A), although treated mice failed to gain body weight (Supplementary Fig. S12). 
The reduced tumor volume, was accompanied by a moderate but significant decrease in the Ki67 proliferation 
index (Fig. 6B), as well as Cyclin D1 and D3 expression in ADI-PEG20 treated xenografts and (Fig. 6C and D). 
Finally, as observed in vitro, ASS1 protein levels were increased in tissue isolated from arginine-deprived animals 
(Fig. 6E).
Overall, these data indicate that ADI-PEG20 treatment reduces in vivo tumorigenicity of ASS1-deficient CRC 
cells.
Combination of arginine deprivation with traditional chemotherapy. Chemotherapy based on the 
platinum compound Oxaliplatin and the antimetabolite 5-FU remains a key combination for first line treatment 
of metastatic CRC or in adjuvant settings28,29. Several publications suggest that ADI-PEG20 has a synergistic effect 
when combined with platinum-based compounds9,15,30–32. Hence, we endeavored to assess whether combining 
arginine deprivation therapy with chemotherapy might improve the treatment of CRC. To this end, we investi-
gated effects of combinations on cell growth employing the Chou-Talalay method and the CompuSyn software33 
(Table 1, Supplementary Figs S13 and S14). Arginase treatment mostly resulted in antagonism (Combinatorial 
Index, CI > 1) when tested with either Oxaliplatin or 5-FU. Additive effects (CI = 1) were observed under a 
minority of conditions. Conversely, ADI-PEG20 in combination with Oxaliplatin elicited synergistic growth inhi-
bition in the ASS1-negative cell lines RKO and HT29 (CI < 1). Of note, with the exception of ADI-PEG20-treated 
HT29, we never observed synergism between 5-FU and arginine deprivation therapy, rather, antagonism was the 
most common outcome of co-treatments.
Overall, these combinatorial studies outline a complex interaction between arginine deprivation and chemo-
therapy. Whereas arginase treatment often appears to be antagonistic with chemotherapeutic drugs, ADI-PEG20, 
in some circumstances, displays synergism in ASS1-deficient cells.
Discussion
ADI-PEG20 and rhArg1peg5000 (BCT-100) are under intense clinical testing in numerous malignancies. 
ADI-PEG20 degrades arginine into citrulline and ammonia, whereas rhArg1peg5000 generates ornithine and 
urea. Resistance of cells against these drugs depends on the expression of the urea cycle enzymes which are 
capable of resynthesizing arginine from the catabolic products. Expression of ASS1 and ASL is necessary for 
resistance to ADI-PEG20 monotherapy34, whereas resistance to arginase requires the additional expression of 
the enzyme OTC19. When investigating biomarkers of arginine auxotrophy in CRC, we recorded a consistently 
poor expression of the urea cycle enzyme OTC in CRC specimens. In mammals OTC protein is expressed only 
in the liver and intestine35 and catalyzes the reaction between carbamoyl-phosphate and ornithine to generate 
citrulline1. This reaction is enabled by the Carbamoyl-Phosphate Synthase 1 (CPS1)-mediated biosynthesis of 
carbamoyl-phosphate, which channels nitrogen from glutamine into the urea cycle. The reason for OTC down-
regulation in CRC remains unclear. Loss of ASS1 expression has been associated with poor prognosis in bladder 
cancer and glioblastoma4,8 and recent data indicate that ASS1 downregulation supports cancer growth allow-
ing aspartate channeling into pyrimidine biosynthesis36. With regard to regulation of urea cycle enzymes, CRC 
is anomalous as OTC downregulation is often accompanied by high expression of ASS116. In CRC, ASS1 has 
been proposed to support proliferation of cancer cells, possibly through the enhancement of the glycolytic flux37. 
Interestingly, preliminary evidence suggests that CPS1 is also downregulated in advanced CRC38, intimating that 
the entire pathway leading to citrulline production is compromised. The reason for this phenomenon is not clear, 
but it is tempting to speculate that lack of OTC and CPS1 expression enable recycling of nitrogen for reactions 
such as nucleotide, amino acid, or polyamine biosynthesis. Whatever the benefit, OTC downregulation renders 
cancer cells sensitive to treatment with human arginase, independently of ASS1 expression. Indeed, our in vivo 
studies show that pegylated arginase diminish the growth of both ASS1-positive and negative CRC cells. This 
finding is particularly interesting, as the potential therapeutic benefit of arginase in the treatment of solid tumors 
has hitherto been rarely investigated19,39,40, even though it has been well-established in blood malignancies17,41–44.
Intriguingly, our TMA analysis indicates that in a fraction of CRC patients ASS1 is poorly expressed or unde-
tectable, an occurrence mirrored by RKO and HT29 cell lines, which both demonstrated significant sensitivity 
to arginine deprivation via ADI-PEG20 treatment in vitro and in vivo. These data intimate that a subset of CRC 
patients may be eligible to treatment with arginine deiminase, although the rapid reappearance of ASS1 in cells 
treated with ADI-PEG20 monotherapy is suggestive of a rapid adaptation and fast ensuing resistance. Indeed, 
restored expression of ASS1 has been reported in patients treated with single agent ADI-PEG2045 and it is a 
common mechanism of acquired resistance against arginine deprivation25,34,46. Our data indicate that a similar 
www.nature.com/scientificreports/
9SCieNtifiC RePoRTS |  (2018) 8:12096  | DOI:10.1038/s41598-018-30591-7
Figure 6. Pharmacological depletion of arginine using ADI-PEG20 reduces tumor growth in vivo. (A) 
Tumor xenografts growth in athymic nude mice subcutaneously injected with 106 RKO CRC cells. Mice 
were randomized into Control (n = 8) and Treatment (n = 8) groups. Treated mice were administered 
intraperitoneally (IP) with 5IU of ADI-PEG20 per animal per week, while control mice were injected with 
equal volume of PBS. Data are plotted as mean ± SEM and were analyzed using mixed linear regression analysis 
(P = 0.045, P < 0.05 indicates a statistically significant difference in tumor growth rate between control and 
treated animals over time). (B) Representative images of ki67-stained xenograft tumors and ki67 proliferation 
index of tumors from vehicle-treated and ADI-PEG20-injected animals. Data are presented as mean ± SEM 
(n = 7 animals per group). *P < 0.05, two-tailed t-test. Size bars = 100 μm. (C) Western blot analysis of the cell 
cycle markers Cyclin D1 and D3 and urea cycle enzyme ASS1 in xenograft tumors isolated from PBS-injected 
controls and ADI-PEG20-treated animals. Actin was used as endogenous loading control. Original western 
blots are reported in Supplementary Fig. S15. (D) Graph bars show quantification of Cyclins levels using 
Image J software. Data are presented as mean ± SEM (n = 7 animals per group). *P < 0.05, two-tailed t-test. 
(E) Representative images of ASS1-stained xenograft tumors and ASS1 H-score index of tumors from vehicle-
treated and ADI-PEG20-injected animals. Data are presented as mean ± SEM (n = 7 animals per group). 
**P < 0.01, two-tailed t-test. Size bars = 100 μm.
www.nature.com/scientificreports/
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re-expression of ASS1 activity is likely to occur in CRC, but, surprisingly, we did not observe re-expression of 
OTC, at least under the experimental conditions used. Currently, the mechanism mediating this persistent loss of 
OTC expression remains elusive, although experiments with the DNA methylase inhibitor suggest that it is likely 
to be independent of promoter methylation.
In several malignancies, ADI-PEG20 synergizes with platinum based chemotherapy9,15,30,31, and a recent 
clinical trial reinforces the relevance of this interaction in combination with the folate antagonist pemetrexed 
in thoracic malignancies32. Chemotherapy of CRC relies on oxaliplatin and 5-FU (FOLFOX), and an ongoing 
clinical trial (NCT02102022) aims at treating patients with advanced gastrointestinal malignancies, including 
CRC, with a combinations of ADI-PEG20 and FOLFOX therapy. This projected trial inspired us to search for 
synergistic interactions between arginine degrading enzymes and the chemotherapeutic drugs oxaliplatin and 
5-FU. Unexpectedly, arginase and arginine deiminase behaved dissimilarly in the combination studies. We failed 
to identify synergistic effects of rhArg1peg5000, which mostly antagonized both oxaliplatin and 5-FU, whereas 
ADI-PEG20 showed either synergistic or antagonistic effects, depending on drug used in the combination and 
cell line. We observed synergism between ADI-PEG20 and oxaliplatin in ASS1-deficient CRC cell lines, but we 
only observed synergism with 5-FU in ASS-1-negative HT29 cells. Therefore, our data warrant caution when 
using arginine deprivation therapy in combination with traditional chemotherapy in CRC, as patients’ responses 
might differ substantially, perhaps consistent with the well-established molecular heterogeneity of colon malig-
nancies47. On the other hand, the evidence of synergistic interactions intimates interesting therapeutic oppor-
tunities, at least for a subset of patients. Indeed, in a clinical study combining ADI-PEG20 with nab-paclitaxel 
and gemcitabine in pancreatic cancer, objective results were observed in both ASS1-proficient and -deficient 
patients48. This suggests that ASS1-deficiency may be less relevant if ADI-PEG20 is combined with other anti-
cancer agents. Also, some malignant cell lines downregulate ASS1 expression when exposed to ADI-PEG2034, 
suggesting that they may be more sensitive to ADI-PEG20 monotherapy, as well as ADI-PEG20 combination 
therapy. Furthermore, ADI-PEG20 inhibits migration of endothelial cells, even when co-cultured with ASS1 
proficient tumors, at least in part by altering the composition and distribution of filamentous actin and attenu-
ating tumor-produced vascular endothelial growth factor49. This demonstrates that, in some cases, ADI-PEG20 
can alter tumor growth in an ASS1-proficient environment, similarly to what we observed with ASS1-positive 
HCT116 cells. Thus, in the absence of rigorous predictive biomarkers that identify synergistic outcomes, it is 
intriguing to envisage that patient derived xenograft avatars, 3-dimensional organoid cultures or tumor tissue 
explants50–52 could be implemented to predict individual patient’s response and to identify those subjects likely 
to benefit from ADI-PEG20 and FOLFOX co-treatment. Similarly, the use of arginine deprivation therapy as 
single treatment remains a promising therapeutic strategy that warrant further investigation in the preclinical 
and clinical settings.
Materials and Methods
TMA Patient cohort. The patient cohort was retrospectively acquired from the Grampian Biorepository 
(www.biorepository.nhsgrampian.org) and contains tissue samples from 650 patients who had undergone sur-
gery for primary CRC between 1994 and 2009 at Aberdeen Royal Infirmary (Aberdeen, UK). Exclusion criteria 
included patients who had received neoadjuvant chemotherapy or radiotherapy. The median survival was 103 
months (95% CI = 86–120 months), the mean survival was 115 months (95% CI = 108–123 months) and the 
median follow-up time (“reverse Kaplan-Meier” method) was 88 months (95% CI = 79–97 months). Clinical-
pathological characteristics of the patients are summarized in Supplementary Table S1.
TMA also contains 50 normal colon mucosal samples acquired from at least 10 cm distant from the primary 
cancer TMA and was constructed as previously described53–55. All the cases were reviewed and areas of tissue to 
be sampled were first identified and marked on the appropriate haematoxylin and eosin stained slide by an expert 
ADI-PEG20 rhArg1peg5000
IC50 IC90 IC50 IC90
5-FU
HCT116 1.42 1.25 1.73 1.63
SW480 — — 1.76 1.08
RKO 1.18 1.1 1.05 1.09
HT29 0.89 0.80 1.41 1.25
Oxaliplatin
HCT116 1.24 1.46 1.92 1.60
SW480 — — 1.54 1.22
RKO 0.61 0.80 1.89 1.59
HT29 0.61 0.80 1.33 1.09
Table 1. Combination studies between ADI-PEG20 or rhArg1peg5000 and chemotherapy. CI values are 
reported for both IC50 and IC90 combinations in the indicated cell lines. CI < 1 indicates synergism, CI = 1 
indicates addictive effect, CI > 1 indicates antagonism. Cells were counted after 6 days of treatment and data 
obtained from diagonal constant ratio combinations were analyzed for synergism, additivity or antagonism 
using the CompuSyn Software (CompuSyn Inc.) according to the Chou and Talalay method.  Bold highlights 
significant synergisms (P < 0.05).
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consultant gastro-intestinal pathologist. Two cores each measuring 1 mm in diameter were taken from areas of 
the corresponding FFPE block and placed in a recipient paraffin block.
The use of human colorectal tissue samples in this study was approved by the Grampian Biorepository sci-
entific access group committee (TR000054). No written consent was required for the use of FFPE tissue samples 
in the CRC TMA. All animal work was carried out under the PPL# 60/4370 in accordance with the Animals 
Scientific Procedures Act of 1986. Animal research was approved by the local ethical committee at the University 
of Leicester.
TMA slides were processed according to standard immunohistochemical protocol described below. 
Expression levels of ASS1 and OTC were assessed blindfolded using PathXL (Clinical Pathology platform) and 
the semi quantitative approach of H-Score. Results were validated against automated classification of expression 
levels using Aperio ImageScope (Leica) and analyzed for agreement using the Cohen’s Kappa coefficient.
Cell Culture and drugs. All cell lines were maintained in a humidified incubator (37 °C, 5% CO2). HCT116 
cells were cultured in McCoy’s 5A + GlutaMAX™ + 10% FCS, SW480 and HT29 in Dulbecco’s Modified Eagle’s 
Medium (DMEM) (4500 mg glucose/L) + GlutaMAX™ + 10% FCS, RKO in Minimum Essential Medium Eagle 
(MEM) + GlutaMAX™ + 10% FCS. All treatments were in DMEM/F12 (1:1) + GlutaMAX™ and 10% FCS. Cells 
were exposed to 1 µg/mL ADI-PEG20 (Polaris Pharmaceuticals, San Diego, CA, USA), or 0.5 µg/mL rhArg-
1peg5000 (Bio-Cancer Treatment International, Hong Kong) or 5 µM of 5-Aza-2′-deoxycytidine (Sigma, UK) or 
vehicle phosphate-buffered saline (PBS, Thermo-Scientific, UK) control, unless stated otherwise. Oxaliplatin and 
5-FU were purchased from Sigma and formulated according to manufacturer’s instructions.
Cell Proliferation Assays. 4000/well cells were seeded in 24-well plates 24 h before treatment. After 24 h 
cells were counted (day 0) and changed to DMEM/F12 (1:1) (Gibco®, UK) + 10% Dialyzed Fetal Bovine Serum 
(FBS) (GE Healthcare Life Sciences) containing various concentrations of drugs or arginine. Quadruplicate sam-
ples of each concentration were assessed for cell growth by cell counting with the Beckman Z™ Series Coulter 
Counter. Prior to cell counting, the treatment media was discarded, cells were washed with PBS and trypsinised 
with 2x Trypsin-EDTA. Trypsin was neutralized with medium and 1 mL of cell suspension was transferred into 
a Coulter cup with 9 mL of Coulter® Isoton® II diluent (Beckman Coulter, UK). Cells were counted between 
8–20 µm.
Drug Combination studies and evaluation of synergy. Single drug IC50 values obtained from corre-
sponding dose-response curves were used for the design of the combination experiments. In a checkerboard 6 × 6 
layout; drug concentrations were crossed combined at an equipotency ratio [(IC50)1/(IC50)2] to ensure that the 
observed effects were achieved by equal contribution of both drugs. Cells were counted after 6 days of treatment 
and data obtained from diagonal constant ratio combinations were analyzed for synergism, additivity or antago-
nism using the CompuSyn Software (CompuSyn Inc.) according to the Chou and Talalay method33.
EdU Incorporation. 106 cells were seeded 24 h before treatment and then changed to medium containing 
arginine catabolizing agents for 72 h. Prior to FACS analysis cells were pulsed with 10 µM 5-ethyl-2′-deoxyuridine 
(EdU) for 1 h, harvested according to routine tissue culture protocols and washed with 1% BSA in PBS. After fix-
ation and permeabilization, cells were incubated 15 minutes at room temperature protected from light. Click-iT® 
Reaction Cocktail was added to cells according to manufacturer’s instructions. Samples were incubated at room 
temperature for 30 minutes protected from light. Total DNA was stained with 1 µL FxCycleTM Violet stain (Life 
Technologies, UK) in samples containing 1 mL cell suspension. Samples were incubated for additional 30 minutes 
on ice in the dark. Samples were analyzed on BD FACSARIATM II, using 405 nm excitation and 450/50 band-pass 
emission for total DNA content, whereas a 488 nm excitation with a green emission filter (530/30 nm) was used 
for detection of EdU with Alexa Fluor® 488 azide. Samples of untreated cells, stained and unstained with EdU or 
FxCycleTM, were also included.
Antibodies. The antibody against ASS1 was kindly provided by Polaris Pharmaceuticals Inc. Antibodies tar-
geting Cyclin D1 (DCS6 and 92G2) and Cyclin D3 (DCS22), total (53H11) total and phospho (Thr37/46) (236B4) 
4E-BP1, total (5G10) and phospho (Ser235/236) (D57.2.2E) ribosomal protein S6, and total/cleaved-PARP 
(46D11) were from Cell Signalling Technology (Leiden, The Netherlands). Actin (C-11) primary antibody and 
secondary mouse (sc-2005), rabbit (sc-2030) and goat (sc-2020) antibodies were purchased from Santa Cruz. 
OTC (ab91418) and Ki67 (ab833) antibodies were from Abcam (Cambridge, MA, USA). All primary antibodies 
for western blotting were diluted at in 3% BSA at a working concentration 1:1,000 overnight. All secondary anti-
bodies were diluted at 1:10,000 in 3% milk.
Western-blot. Whole-cell lysates of CRC cell lines and xenograft tissues were prepared in Complete Lysis-M 
buffer (Roche, Germany). Protein quantification was performed using the Pierce™ BCA protein assay (Thermo 
Fisher Scientific, UK). 30 µg of total protein per lane was loaded on acrylamide gel. Following the SDS-PAGE elec-
trophoresis, proteins were transferred to a nitrocellulose membrane (Geneflow, UK), blocked for 1 h in 5% milk 
and incubated overnight with primary antibodies at 4 °C. Membranes were then washed with PBS-0,01%Tween 
(SIGMA, UK) and incubated with appropriate secondary antibodies at room temperature for 1 h. Proteins were 
visualized using the Enhanced Chemiluminescence Luminol (ECL) reagent (Geneflow Ltd., UK). Images were 
captured using the GeneGnome XRQ system (Syngene, UK) or Kodak X-Ray films. The protein band intensity 
was measured using ImageJ software and the relative expression levels of the proteins were normalized against 
actin. The protein band intensity was measured using densitometry performed with ImageJ software. Proteins 
www.nature.com/scientificreports/
1 2SCieNtifiC RePoRTS |  (2018) 8:12096  | DOI:10.1038/s41598-018-30591-7
presented as double bands were selected and quantified as a whole. The relative expression levels of the proteins 
were normalized against actin.
Immunohistochemistry (IHC). The immunostaining was performed using NovolinkTM Polymer Detection 
System (Leica Biosystems, UK). Following deparaffinization, rehydrated sections were boiled for 20 minutes in 
antigen retrieval buffer (1X Tris-EDTA, pH 9). Endogenous peroxidase activity was neutralized using peroxi-
dase block for 5 minutes. Sections were then blocked in protein block buffer for 30 minutes and incubated with 
primary antibodies for 2 h at room temperature. Peroxidase chromogenic reaction was developed with DAB 
working solution according to manufacturer’s instructions. Slides were counterstained with haematoxylin and 
mounted with DPX mounting media and scanned with Hamamatsu NanoZoomer-XR Digital scanner. Staining 
was evaluated with Aperio ImageScope software (Leica) and the semi-quantitative H-score calculated using the 
following formula:
+ + .[1x (% weak positive cells) 2x (% positive cells) 3x (% strong positive cells)]
In vivo xenograft studies. 8-week-old, female Foxn1nu mice were purchased from Charles River, UK. Mice 
were kept in ventilated cages exposed to 12 h light/dark cycles under pathogen free conditions. Prior to xenograft-
ing, HCT116-luc2 (Perkin Elmer), RKO and SW480 cells were harvested at 70–80% confluency and resuspended 
to a final concentration of 107 cells per 1 ml Matrigel (BD Biosciences):Serum Free medium [1:1]. 106 cells were 
then injected subcutaneously unto the flank of each animal. A week after, mice with established tumors were 
randomized and treated with ADI-PEG20 5IU/animal once a week or rhArg1peg5000 5 mg/animal twice a week 
or vehicle control (PBS). Mice bearing HCT116 tumors were randomized to arginine-free diet (57M7) or control 
diet (5CC7) (TestDiet®) right after the initial cell injections. Body weight and tumor size were measured weekly. 
Further to the manual measurements, mice bearing HCT-116 luc2 tumors were monitored via the IVIS Spectrum 
Preclinical Imaging System (PerkinElmer®) once a week. Prior to in vivo imaging mice were administered sub-
cutaneously with 150 mg/kg Xenolight RediJect D-Luciferin (PerkinElmer®), anesthetised and imaged with IVIS 
10 minutes post injection. When tumors reached 17 mm diameter animals were sacrificed under terminal anes-
thesia (3–5% Isoflurane). Blood was collected by cardiac puncture. Tumors were excised, weighted, and fixed in 
formalin or snap-frozen. Study groups were not based on power calculations and experimenters were not blinded 
to the randomly allocated treatment groups.
Statistical analysis. The error bars represent the ±Standard Error of the Mean (±SEM). Statistical signif-
icance between two groups was determined by two-tailed unpaired Student’s t-test, whereas multiple One-Way 
Anova analysis was conducted to compare controls against multiple drug concentrations (Prism version 7.0, 
GraphPad Software, Inc.). The animal xenograft studies were assessed for statistical significance using the mixed 
linear regression model in Stata software (StataCorp LP, College Station, TX, USA). Statistical analysis of TMA 
cohort patient data including the Mann-Whitney U test, Wilcoxon signed rank test, chi-squared test, and Cox 
multi-variate analysis (variables entered as categorical variables) was performed using IBM SPSS version 24 for 
Windows 7TM (IBM, UK).
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